(MedPage Today) — Chimeric antigen receptor (CAR) T-cell therapies pose no special safety issues for cancer patients with comorbid autoimmune diseases, and while so-called checkpoint inhibitors for cancer do come with increased risk for acute…
Source link : https://www.medpagetoday.com/rheumatology/generalrheumatology/114007Author :
Publish date : 2025-01-30 16:37:35
Copyright for syndicated content belongs to the linked
Source.